Aperio Group LLC boosted its holdings in shares of Core Laboratories N.V. (NYSE:CLB) by 86.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,940 shares of the oil and gas company’s stock after acquiring an additional 5,058 shares during the period. Aperio Group LLC’s holdings in Core Laboratories N.V. were worth $1,080,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Parallel Advisors LLC raised its position in Core Laboratories N.V. by 13.1% during the second quarter. Parallel Advisors LLC now owns 1,008 shares of the oil and gas company’s stock worth $101,000 after acquiring an additional 117 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Core Laboratories N.V. by 63.7% during the second quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock worth $114,000 after acquiring an additional 439 shares during the last quarter. Shine Investment Advisory Services Inc. acquired a new position in Core Laboratories N.V. during the second quarter worth about $134,000. Advisory Services Network LLC raised its position in Core Laboratories N.V. by 33.3% during the second quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock worth $138,000 after acquiring an additional 341 shares during the last quarter. Finally, First Bank & Trust raised its position in Core Laboratories N.V. by 5.8% during the second quarter. First Bank & Trust now owns 1,493 shares of the oil and gas company’s stock worth $152,000 after acquiring an additional 82 shares during the last quarter.

A number of brokerages have issued reports on CLB. Zacks Investment Research cut shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. UBS AG cut their price objective on shares of Core Laboratories N.V. from $110.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, October 25th. ABN Amro raised shares of Core Laboratories N.V. from a “hold” rating to a “buy” rating in a research report on Wednesday, October 25th. Loop Capital cut their price objective on shares of Core Laboratories N.V. from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Wednesday, October 25th. Finally, Scotiabank set a $136.00 price objective on shares of Core Laboratories N.V. and gave the company a “hold” rating in a research report on Wednesday, October 25th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $108.64.

Shares of Core Laboratories N.V. (CLB) opened at $100.51 on Friday. Core Laboratories N.V. has a twelve month low of $86.55 and a twelve month high of $125.83. The stock has a market cap of $4,437.21, a P/E ratio of 54.92 and a beta of 1.57. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.18 and a quick ratio of 1.81.

Core Laboratories N.V. (NYSE:CLB) last released its earnings results on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.04. Core Laboratories N.V. had a net margin of 12.06% and a return on equity of 52.89%. The firm had revenue of $166.20 million during the quarter, compared to the consensus estimate of $160.94 million. During the same period in the previous year, the firm earned $0.38 earnings per share. Core Laboratories N.V.’s revenue was up 1.4% compared to the same quarter last year. equities analysts anticipate that Core Laboratories N.V. will post 1.99 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 21st. Investors of record on Friday, October 20th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Thursday, October 19th. This represents a $2.20 dividend on an annualized basis and a yield of 2.19%. Core Laboratories N.V.’s payout ratio is 126.44%.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/11/19/aperio-group-llc-increases-holdings-in-core-laboratories-n-v-clb.html.

Core Laboratories N.V. Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.